Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Abstract:Clinical and Translational MedicineVolume 10, Issue 4 e157 LETTER TO EDITOROpen Access An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion Yan Mei, Yan Mei State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorYing-He Li, Ying-He Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorXiao-Chun Yang, Xiao-Chun Yang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorChao Zhou, Chao Zhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorZhi-Jian Li, Zhi-Jian Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorXiao-Bin Zheng, Xiao-Bin Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorJia-Cong Ye, Jia-Cong Ye State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorCheng Li, Cheng Li School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, ChinaSearch for more papers by this authorXuan-Hong Zhang, Xuan-Hong Zhang Experimental Equipment Management Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, ChinaSearch for more papers by this authorJian-Min Yuan, Jian-Min Yuan Central Research Institute UIH Group, Shanghai, ChinaSearch for more papers by this authorHui-Qiang Huang, Hui-Qiang Huang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei Fan, Wei Fan State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei-Guang Zhang, Corresponding Author Wei-Guang Zhang zhangwg@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorMu-Sheng Zeng, Corresponding Author Mu-Sheng Zeng zengmsh@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorGuo-Kai Feng, Corresponding Author Guo-Kai Feng fengguok@sysucc.org.cn orcid.org/0000-0002-8251-291X State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this author Yan Mei, Yan Mei State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorYing-He Li, Ying-He Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorXiao-Chun Yang, Xiao-Chun Yang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorChao Zhou, Chao Zhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorZhi-Jian Li, Zhi-Jian Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorXiao-Bin Zheng, Xiao-Bin Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorJia-Cong Ye, Jia-Cong Ye State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorCheng Li, Cheng Li School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, ChinaSearch for more papers by this authorXuan-Hong Zhang, Xuan-Hong Zhang Experimental Equipment Management Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, ChinaSearch for more papers by this authorJian-Min Yuan, Jian-Min Yuan Central Research Institute UIH Group, Shanghai, ChinaSearch for more papers by this authorHui-Qiang Huang, Hui-Qiang Huang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei Fan, Wei Fan State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei-Guang Zhang, Corresponding Author Wei-Guang Zhang zhangwg@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorMu-Sheng Zeng, Corresponding Author Mu-Sheng Zeng zengmsh@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorGuo-Kai Feng, Corresponding Author Guo-Kai Feng fengguok@sysucc.org.cn orcid.org/0000-0002-8251-291X State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this author First published: 26 August 2020 https://doi.org/10.1002/ctm2.157Citations: 4 AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Dear Editor, Recently, we successfully developed a radiolabeled probe targeting integrin α6 for the positron emission tomography (PET)/magnetic resonance (MR) imaging of pancreatic ductal adenocarcinoma (PDAC) and its precancerous lesion, pancreatic intraepithelial neoplasia (PanIN). Most pancreatic cancers are PDAC.1 Standard approaches for detecting PDAC at early stage are lacking with most diagnosed patients at advanced stage.2 Tumor-targeted molecular imaging significantly improved the tumor-detection rate,3 which may also enhance the early diagnosis of PDAC. Considering the genetic complexity of PDAC, a PDAC-specific target with highly adaptability, sensitivity, and specificity is required. We selected integrin α6 as the target of PDAC as it was overexpressed in pancreatic cancer cells4, 5 and cancerous tissue of patients with PDAC4, 6, 7 with an overexpression rate up to 92%.4 Increased integrin α6 levels were associated with stronger PDAC cell invasiveness5 and poorer prognosis for patients.6, 7 Furthermore, the integrin α6β4 dimer was overexpressed in PanIN even at a stage as early as PanIN 1A.4 Here, we confirmed that integrin α6 was overexpressed in human PDAC (Figure 1A,B) and increased integrin α6 had poorer prognosis for PDAC patients (Figure 1C). Recently, a peptide CRWYDENAC (dubbed RWY) targeting integrin α6 has been identified8 and employed for nanotherapeutics of nasopharyngeal carcinoma8 and for PET imaging of hepatocellular carcinoma by our team.9 Here, we used the Ala scanning mutagenesis to modify the RWY peptide. R, W, and Y were the three key amino acids within the RWY peptide, since their replacement by an alanine reduced the cellular binding ability of this peptide, both in vitro and in vivo. Interestingly, the alanine substitution of E resulted in the CRWYDANAC (dubbed S5) peptide with an approximately 1.5-fold enhanced tumor binding ability (Figure 1D,E). The higher binding affinity of S5 peptide to tumor cells was further confirmed in vitro by flow cytometry (Figure 1F,G) and in vivo in PDAC mouse model using optical imaging (Figure 1H,I). FIGURE 1Open in figure viewerPowerPoint Increased and poorer prognosis of integrin α6 in PDAC and the optimization of a peptide targeting integrin α6. A, According to the TCGA database, increased integrin α6 expression was observed in tumor tissues of PADC patients. B and C, Based on the GEPIA database, patients with higher integrin α6 expression in the tumor tissue showed a poorer prognosis for overall and disease-free survival. D, The binding affinities of seven Ala-mutated peptides were analyzed by ELISA. E, The in vivo blocking assays were performed via intravenous injection of 6 nmol of Cy5-RWY together with 6 μmol of the unlabeled RWY peptide, or its scrambled peptide or a set of its alanine-scanning mutant peptides into mice bearing Sw1990 tumors. The S5 peptide had the highest blocking effect on Cy5-RWY. F and G, Sw1990 cells were incubated with Cy5-RWY and Cy5-S5 at 37°C for 30 min, and the integrin α6-binding affinities of Cy5-RWY and Cy5-S5 were analyzed by flow cytometric analysis (F); the fluorescence intensity of the S5 group presented as relative (1.41 ± 0.03) fold over RWY, indicating a higher tumor cell-binding ability of S5. H and I To further investigate the in vivo tumor-binding ability of the S5 peptide, Cy5-S5, Cy5-RWY, and Cy5-CG7C (negative control) were synthesized and used in NIRF. In the in vivo NIRF imaging of mice bearing subcutaneous Sw1990-luciferase xenografts, Cy5-S5 exhibited higher fluorescence intensity in tumor location (black arrow: the xenograft) (H); the fluorescence intensity of Cy5-S5 presented as relative fold over RWY (2.64 ± 0.09) was significantly higher than that of Cy5-RWY (1.00 ± 0.10, P = .000) (mean ± SD, ANOVA in (D) and (E) and Student's t-test in (G) and (I) were used for statistical analysis. *P < .05, **P < .01, ***P < .001. NS, not significant) The recently introduced PET/MR imaging technique displays certain advantages in tumor imaging and has potential applications in the imaging of early pancreatic cancer.10 Thus, we synthesized the radiotracer 18F-NOTA-PEG4-S5 (18F-S5 for short) for the PET/MR imaging (Figure S1A). 18F-S5 was stable in serum (Figure S1B), and it showed ideal biodistribution characteristics in vivo that the uptake of 18F-S5 in tumor tissues was the highest among all collected tissues and organs except for the kidney (Figure S1C,D, Table S1). The convenience of 18F-S5-PET/MR imaging on PDAC and PanIN was proved in four mice models. Approximately 3.7 × 106 Bq (100 μCi) of 18F-S5 was intravenously injected to a mouse for PET imaging, and 2.5 mmol/kg of gadolinium-diethylenetriamine pentaacetic acid was injected for enhanced MR imaging. After 120 min postinjection of 18F-S5, PET/MR imaging was obtained by using a hybrid 3.0T PET/MR scanner (uPMR 790; UIH, Shanghai, China). The PDAC-targeting effect of 18F-S5 was preliminary examined in a subcutaneous Sw1990-luciferase tumor-bearing mouse model, where the tumor-to-muscle ratio reached 3.62 ± 0.25 in unblocked mice and significantly decreased to 1.62 ± 0.05 when the binding was blocked by nonradiolabeled S5 (Figure S2A-D). Similar results were observed in the orthotopic Sw1990-luciferase mouse model with a tumor-to-muscle ratio of 3.48 ± 0.62 (Figure S2E-G). In the genetically engineered KPC mice (LSL-KrasG12D/+; Pdx1-Cre; Trp53fl/fl) with spontaneously developed PDAC, a routine MR scan showed no abnormal signal in pancreas on T1 weighted images, and the tumor only presented as local moderate enhancement on the enhanced MR scans (Figure S3A). However, in the PET/MR imaging, 18F-S5 produced high PET signals in the possible location of the tumor (Figure 2A). The uptake of 18F-S5 in tumor was quantified as 4.34 ± 1.16 %ID/g (a percentage of the injected dose per gram) (n = 5) and the tumor-to-muscle ratio was 4.32 ± 0.65 (Figure 2B). The pancreas of the KPC mouse displayed morphological changes compared with the pancreas of a healthy mouse (Figure 2C). The overexpression of integrin α6 in the spontaneously developed PDAC tissue was confirmed using immunohistochemistry (Figure 2D). In addition, 18F-S5-PET/MR imaging could also detect metastatic tumors in KPC, where 18F-S5 produced high PET signals in both of the PDAC lesions and the metastatic tumors in the abdominal cavity (Figure S4A-D). Furthermore, 18F-S5-PET/MR imaging could detect precancerous lesions of PDAC in the KC mice (LSL-KrasG12D/+; Pdx1-Cre) with spontaneous developed PanIN (Figure 2E), which was undetectable when enhanced MR imaging was used alone (Figure S3B). 18F-S5 showed a high accumulation in the possible lesion site, as the quantified uptake was 2.99 ± 0.52 %ID/g and the PanIN-to-muscle ratio was 3.35 ± 0.43 (Figure 2F). The pancreas of the KC mouse displayed morphological changes as its outer surface was rougher (Figure 2G ) than that of the normal pancreas, as shown in Figure 2C. Immunohistochemical analysis confirmed the formation of PanIN lesions in the pancreas and increased integrin α6 expression in lesion tissues (Figure 2H). FIGURE 2Open in figure viewerPowerPoint 18F-S5 PET/MR imaging in PDAC and PanIN mouse models. A, Representative cross-sectional images of PET/MR imaging with 18F-S5 of KPC mouse (left) and the 3D image (right). B, Quantification of 18F-S5 uptake (%ID/g) by KPC mouse in tumor (4.34 ± 1.16), muscle (1.00 ± 0.17), liver (1.24 ± 0.33), and heart (2.38 ± 0.45), respectively. C, The pancreas of the KPC mouse showed an abnormal appearance compare to the pancreas of a healthy mouse. D, The development of PDAC in KPC mouse was confirmed by HE staining (left), and increased integrin α6 expression was confirmed by immunohistochemistry (right). E, Representative cross-sectional images of PET/MR imaging of KC mouse (left) and the MIP reconstructed image (right). F, Quantification of 18F-S5 uptake (%ID/g) by KC mouse in PanIN tissue (2.99 ± 0.52), muscle (0.89 ± 0.13), liver (1.31 ± 0.22), and heart (2.43 ± 0.35), respectively. G, The pancreas of the KPC mouse showed an abnormal appearance compare to the pancreas of a healthy mouse. H, The development of PanIN in mice was confirmed by HE staining (left), and the overexpression of integrin α6 in the lesion was analyzed using immunohistochemistry (right) (red arrow: PanIN; black arrow: relatively normal pancreatic tissue) (mean ± SD, the difference was evaluated by Student's t-test, *P < .05, **P < .01, ***P < .001) In summary, we developed an optimized integrin α6-targeted radiolabeled probe, 18F-S5, for PET/MR imaging of PDAC and PanIN in mice models. 18F-S5 displayed ideal stability and biodistribution characteristics, and it enabled the detection of PDAC at an early stage with high sensitivity, a favorable tumor-to-muscle ratio, and low liver uptake in mice, which suggests its potential clinical translation. ACKNOWLEDGMENTS This work was supported by grants from the National Key R&D Program of China (2017YFA0505600 and 2016YFA0502100), the National Natural Science Foundation of China (NSFC) (projects 81972531, 81602364, 81621004, 81520108022, and 81572403), the National Science & Technology Major Project (2017ZX09304021), and the Science & Technology Project of Guangdong Province (2017A020211010). The approval Research Data Deposit number was RDDB2020000944. CONFLICT OF INTEREST The authors have declared that no competing interest exists. ETHICS APPROVAL The animal experiments were approved by the animal welfare and ethics committees of Sun Yat-sen University Cancer Center. Open Research DATA AVAILABILITY STATEMENT The raw data used in this article have been uploaded onto the Research Data Deposit public platform (www.researchdata.org.cn). Supporting Information Filename Description ctm2157-sup-0001-SuppMat.docx245.1 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019; 69(1): 7- 34. 2Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016; 388(10039): 73- 85. 3Yao VJ, D'Angelo S, Bulter KS, et al. Ligand-targeted theranostic nanomedicines against cancer. J Control Release. 2016; 240: 267- 286. 4Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL. Upregulation and redistribution of integrin α6β4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol. 2007; 20(6): 656- 667. 5Wu Y, Tan X, Liu P, et al. ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. Exp Cell Res. 2019; 379(1): 30- 47. 6Sawai H, Funahashi H, Matsuo Y, et al. Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci. 2003; 48(7): 1241- 1250. 7Zhu G, Huang C, Qiu Z, et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2011; 56(4): 1090- 1098. 8Feng G, Zhang M, Wang H, et al. Identification of an integrin α6-targeted peptide for nasopharyngeal carcinoma-specific nanotherapeutics. Adv Therap. 2019; 2:1900018. 9Feng G, Ye J, Zhang W, et al. Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. J Control Release. 2019; 310: 11- 21. 10Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma. Abdom Radiol. 2018; 43(2): 415- 434. Citing Literature Volume10, Issue4August 2020e157 FiguresReferencesRelatedInformation

In Memory of Hal E. Broxmeyer, a Pluripotent Scientist, Pioneer, and Mentor

Plenary Paper

Editorial: Neuroendocrine Research in Health and Disease

Ott_a_231052 11033..11044

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Contents Vol. 5, 2019

An Optimized Integrin Α6‐targeted Peptide for Positron Emission Tomography/magnetic Resonance Imaging of Pancreatic Cancer and Its Precancerous Lesion

Editorial: Novel Insights in RNA Modifications: from Basic to Translational Research

Research_9802969 1..5

Ott_a_227644 389..399

Amep_a_248210 351..358

A comprehensive repository of mutation data and a clinical assistant decision system for hemoglobinopathy in the Chinese population

Contents Vol. 45, 2011

Ott_a_242517 1757..1765

Dddt_a_354270 817..825

COVID-19 in Hematologic Malignancies: Big Challenges

Profile of Xiyun Yan

Dmso_a_228351 2209..2220

New insights into Human Hematopoietic Stem and Progenitor Cells via Single-Cell Omics

Cmar_a_195964 5187..5195

Ott_a_273823 1007..1020